Results 131 to 140 of about 20,250 (180)

Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial. [PDF]

Acta Oncol
Slørdahl KS, Puco K, Falk RS, Dyvik I, Brabrand S, Niehusmann P, Steinskog ESS, Blix ES, Flobak Å, Oppedal IA, Meltzer S, Torkildsen CF, Blakstad H, Lindemann K, Smeland S, Amundsen A, Taskén K, Helland Å, InPred Consortium.   +18 more
europepmc   +1 more source

Impact of non-genetic heterogeneity of BRAF-mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics. [PDF]

Int J Cancer
Zieger V, Woehr E, Traichel J, Brummer T, Zengerle R, Kartmann S, Zimmermann S.   +6 more
europepmc   +1 more source

Durable complete response to pembrolizumab after BRAF/MEK inhibition in recurrent MSI-H/dMMR, BRAF V600E-mutant colon cancer: a case report. [PDF]

Front Oncol
Yu W, Li K.
europepmc   +1 more source

Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study. [PDF]

NPJ Precis Oncol
Hofmann E, Abu-Sirhan S, Elsholtz F, Piwonski I, Kreutzer K, Doll C, Joosten M, Möbs M, Busch CJ, Fenske B, Knödler M, Pestana A, Hirschhorn A, Heiland M, Keller U, Keilholz U, Klinghammer K, Rieke DT, Schmidt M.   +18 more
europepmc   +1 more source

AP-1 mediates cellular adaptation and memory formation. [PDF]

Nat Commun
Li J, Ravindran PT, O'Farrell A, Busch GT, Boe RH, Niu Z, Woo S, Dunagin MC, Jain N, Goyal Y, Sarma K, Herlyn M, Raj A.   +12 more
europepmc   +1 more source

Therapeutic Drug Monitoring and Model-Informed Precision Dosing of Oral TKIs and PARP Inhibitors: A Practical Framework for Clinical Implementation. [PDF]

Clin Pharmacokinet
Torrent-Rodríguez A, Bastida C, Martín ECS, Escartín IM, Puszkiel A, Blanchet B, Laguna JC, Gorria T, Montes A, Macías I, Alvárez A, Arance A, Moreno FA, Fabregat-Bolufer AB, Soler E, Muner DS.   +15 more
europepmc   +1 more source

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma. [PDF]

Clin Cancer Res
Hollis RL, Miller A, Lankes HA, Wong KK, Rodgers W, Millan D, Carty K, Coleman RL, Moore KN, Alvarez Secord A, O'Malley DM, Chan JK, Hagemann AR, Gaillard S, Guntupalli SR, Edelson MI, Rose PG, Dorigo O, Banerjee S, Ewing A, Churchman M, Sood AK, Herrington CS, Gourley C, Gershenson DM.   +24 more
europepmc   +1 more source

MEK1/2 inhibition prevents DENV and ZIKV infection via disrupting the cytoskeletal vimentin cage required for viral replication. [PDF]

J Mol Cell Biol
Huang Y, Lu J, Cui S, Zhao S, Sun S, Jiu Y.   +5 more
europepmc   +1 more source

MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRAS^Q61R Human Endothelial Cells. [PDF]

Pediatr Blood Cancer
Alharbi S, Wagner A, Merkle S, Pastura P, McDaniel CG, Fox D, Xu Y, Le Cras TD.   +7 more
europepmc   +1 more source

Proliferation-dependent adipogenic differentiation of progenitor cells in rat coronary artery explants. [PDF]

Stem Cell Res Ther
Kazantzi S, Reducha PV, Haanes KA.
europepmc   +1 more source